Jiangsu Hengrui Pharmaceuticals Company Ltd. (Chinese: 江苏恒瑞医药股份有限公司), also known as Jiangsu Hengrui (Chinese: 恒瑞医药), is a Chinese pharmaceutical company that manufactures and distributes various types of drug packaging materials, cancer-treating antineoplastics, cardiovascular medication, painkillers, antibiotics, and related products.[1][2] It is the largest listed pharmaceutical company in China.[3]
^Profile of Jiangsu Hengrui Medicine Company Limited
^"Search of: Hengrui - List Results - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 22 November 2020.
^China's pharmaceutical industry is poised for major growth
JiangsuHengrui Pharmaceuticals Company Ltd. (Chinese: 江苏恒瑞医药股份有限公司), also known as JiangsuHengrui (Chinese: 恒瑞医药), is a Chinese pharmaceutical company...
hepatocellular carcinoma and Hodgkin lymphoma. This drug is being developed by JiangsuHengRui Medicine Co., Ltd. As of 2019[update], camrelizumab is undergoing Phase...
Chinese pharmaceutical executive and billionaire, the chairman of JiangsuHengrui Medicine. Sun has a bachelor's degree from China Pharmaceutical University...
1016/j.ejphar.2012.11.023. PMC 3534778. PMID 23183107. "Arketamine – JiangsuHengrui Medicine – AdisInsight". Archived from the original on 13 April 2021...
announced that the company's stock would be added to the Hang Seng Index. JiangsuHengrui Medicine "翰森製藥集團有限公司簡介". Archived from the original on 2020-09-26....
International Group 17 99 Sun Piaoyang 65–66 17.1 -US$1.8B The head of JiangsuHengrui Medicine 18 100 Luo Liguo 67–68 17.1 +US$12.8B The chair of Hoshine...
HRS9531 is an experimental GLP-1 and GIPR dual agonist developed by JiangsuHengrui. Goldenberg, Ronald M.; Gilbert, Jeremy D.; Manjoo, Priya; Pedersen...
inhibitor in development for hyperuricaemia and gout. It is developed by JiangsuHengrui. Lin, Yanwei; Chen, Xiaoxiang; Ding, Huihua; Ye, Ping; Gu, Jieruo;...
had gained exclusive development and commercial right pertaining to JiangsuHengrui Medicine Co., Ltd's anti-PD-1 monoclonal antibody, SHR-1210, in a deal...
out global rights to HLB (Korea) in 2020 and is being developed by JiangsuHengrui Medicine (China), LSK BioPartners (US) and HLB Life Science (Korea)...
SSE: 600030 CITIC Securities Financials Shanghai 1.166 SSE: 600276 JiangsuHengrui Medicine Health Care Shanghai 1.068 SSE: 601398 Industrial and Commercial...
pharmaceutical factory in the same city. (That factory would eventually become JiangsuHengrui Medicine, the largest listed pharmaceutical company in China.) In 1995...
PCN-101 by Perception Neuroscience in the United States and HR-071603 by JiangsuHengrui Medicine in China. List of investigational antidepressants Ganellin...
world-class pharmaceutical industry. JiangsuHengrui Medicine Co. Ltd. (SHA: 600276), headquartered in Lianyungang, Jiangsu Province, is one of the leading...
nonsteroidal antiandrogen enzalutamide. The drug was developed by JiangsuHengrui Medicine. Other structural analogues of rezvilutamide that are also...
Famitinib is a tyrosine kinase receptor inhibitor developed by JiangsuHengrui for a variety of cancers. Chen, Li; Jiang, Yi-Zhou; Wu, Song-Yang; Wu,...
SSE: 600030 CITIC Securities Financials Shanghai 2.061 SSE: 600276 JiangsuHengrui Medicine Health Care Shanghai 1.887 SSE: 601398 Industrial and Commercial...
Global Information